1-7 of 7
Lei Zheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

Oliver C. Rogers, Lizamma Antony, Oren Levy, Nitin Joshi, Brian W. Simons, Susan L. Dalrymple, D. Marc Rosen, Andrew Pickering, Haoyue Lan, Heidi Kuang, Sudhir H. Ranganath, Lei Zheng, Jeffrey M. Karp, S. Peter Howard, Samuel R. Denmeade, John T. Isaacs, W. Nathaniel Brennen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2353–2362.
https://doi.org/10.1158/1535-7163.MCT-20-0227
Published: 03 November 2020
View article titled, Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Open the PDF for Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer

Tao Wei, Qi Zhang, Xiang Li, Wei Su, Guogang Li, Tao Ma, Shunliang Gao, Jianying Lou, Risheng Que, Lei Zheng, Xueli Bai, Tingbo Liang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (1): 196–203.
https://doi.org/10.1158/1535-7163.MCT-17-1298
Published: 02 January 2019
View article titled, Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
Open the PDF for Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A207: Utilizing human OX40 knock-in mice (HuGEMMTM) to assess antitumor efficacy of OX40-agonistic antibodies

Xuesong Huang, Lei Zheng, Wenyi Ouyang, Mingkun Zhang, Annie Xiaoyu An, Jing Zhao, Xiang Gao, Jean Pierre Wery, Qian Shi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A207.
https://doi.org/10.1158/1535-7163.TARG-17-A207
Published: 01 January 2018
View article titled, Abstract A207: Utilizing human OX40 knock-in mice (HuGEMM<sup>TM</sup>) to assess antitumor efficacy of OX40-agonistic antibodies
Journal Articles

Abstract A203: Generation of human TIM3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies

Lei Zheng, Xuesong Huang, Wenyi Ouyang, Gang Chen, Annie Xiaoyu An, Xin Dong, Jay Liu, Jean Pierre Wery, Qian Shi, Davy Xuesong Ouyang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A203.
https://doi.org/10.1158/1535-7163.TARG-17-A203
Published: 01 January 2018
View article titled, Abstract A203: Generation of human TIM3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies
Journal Articles

Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment

Agnieszka A. Rucki, Qian Xiao, Stephen Muth, Jianlin Chen, Xu Che, Jennifer Kleponis, Rajni Sharma, Robert A. Anders, Elizabeth M. Jaffee, Lei Zheng
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (11): 2399–2409.
https://doi.org/10.1158/1535-7163.MCT-16-0452
Published: 01 November 2017
View article titled, Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
Open the PDF for Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment in another window
Includes: Supplementary data
Journal Articles

Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Bryan Wei Chen, Wei Chen, Hui Liang, Hao Liu, Chao Liang, Xiao Zhi, Li-qiang Hu, Xia-Zhen Yu, Tao Wei, Tao Ma, Fei Xue, Lei Zheng, Bin Zhao, Xin-Hua Feng, Xue-li Bai, Ting-bo Liang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (8): 1805–1815.
https://doi.org/10.1158/1535-7163.MCT-15-0029
Published: 05 August 2015
View article titled, Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells
Open the PDF for Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells in another window
Includes: Supplementary data
Journal Articles

Abstract A87: Preliminary results of a phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.

Aaron T. Wild, Ariel E. Marciscano, Manuel Hidalgo, Daniel A. Laheru, Dung Le, Amy Hacker-Prietz, Mark A. Ziegler, Barish H. Edil, Phuoc T. Tran, Lei Zheng, Timothy M. Pawlik, Richard D. Schulick, Christopher L. Wolfgang, Joseph M. Herman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A87.
https://doi.org/10.1158/1535-7163.TARG-11-A87
Published: 12 November 2011
View article titled, Abstract A87: Preliminary results of a phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.